DefenAge Skincare has announced it has received a new patent—its “Defensin Master Anti-Aging Patent for Signature Cell Stimulating Technology.” Issued by the US Patent Office, it is (Patent #11,491,096), and it was seven years in the making, the company says.

The patented technology is based on the unique ability of Defensin-molecules to trigger a  powerful regenerative response in the body through activating dormant, “preserved” young skin master cells to generate new, young skin.

DefenAge’s ground-breaking cell stimulating compositions and methods are used in all its products, and the new patent concludes the brand’s patents for the use of Defensin-molecules to reverse signs of skin aging. Its formulas claim to decrease visible fine and coarse wrinkles, pore size, and pigmentation.

How It Works

Defensins activate dormant preserves of “fresh” cells in the body, LGR6-positive skin master cells. After activating, LGR6-positive cells physically migrate into the basal layer of the skin and create a new epidermis, and eventually, new, younger-acting skin, delivering all the advantages of retinols without irritation, inflammation, or sun-sensitivity.

Dermatologist Natalie M. Curcio explains, “Defensins are unique natural molecules that trigger a regenerative response in the skin, similar to the one our body generates during wound healing. Every time a scratch or wound on the skin heals, the skin in the healed (closed) wound area is always younger than the skin around it.”

Curcio continues, “This is because our body activates “preserved” young cells to heal wounds. In other words, the body creates new, young skin to repair wounds. Defensins activate the same mechanism in our body, meaning that every time defensins are applied to the skin, they activate the body to produce new and young skin without a wound.”

Celebrity dermatologist, Dr. Suneel Chilukuri weighs in on the clinical proof, stating, “DefenAge is one of the most rigorously tested and proven modern cosmeceutical products you can find.”

DefenAge’s products and their Defensins were tested in 19 clinical studies, including the ones published in the top peer-review magazines, the Journal of Drugs in Dermatology and Journal of Cosmetic Dermatology.

Chilukuri adds, “The studies show that any part of the skin is able to respond to Defensins, with improvement in a variety of skin qualities addressing almost all aspects of visible skin aging, including the face, skin around the eyes, and body. Even the scalp and skin under the hair improves and normalizes hair growth metrics.”

The brand’s purple packaging utilize airless bottles, airless jars, and a cold-to-the-touch metal applicator, which dispenses the product perfectly around the eye area.